UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2021~~March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

Commission file number 1-225

~~KIMBERLY CLARK CORPORATON~~KIMBERLY-CLARK CORPORATION

(Exact name of registrant as specified in its charter


Delaware						39-0394230
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

P.O. Box 619100

Dallas, TX

75261-9100

(Address of principal executive offices)

(Zip code)

(972) 281-1200

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	KMB	New York Stock Exchange
0.625% Notes due 2024	KMB24	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x

As of ~~July 16, 2021,~~April 15, 2022, there were ~~336,762,087~~336,925,493 shares of the Corporation's common stock outstanding.

Table of Contents


PART I – FINANCIAL INFORMATION			1

Item 1. Financial Statements			1

UNAUDITED CONSOLIDATED INCOME STATEMENTS FOR THE THREE ~~AND SIX~~ MONTHS ENDED ~~ENDED~~ ~~JUNE 30~~M ARCH 3 1 , 202 2 AND 2021 ~~AND 2020~~			1

UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE THREE ~~AND SIX~~ MONTHS ENDED ~~JUNE 30~~MARCH 3 1 , 202 2 AND 2021 ~~AND 2020~~			2

CONSOLIDATED BALANCE SHEETS AS OF ~~JUNE 30~~MARCH 3 1 , ~~2021~~202 2 (UNAUDITED) AND DECEMBER 31, ~~2020~~ 2021			3

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE ~~AND SIX~~ MONTHS ENDED ~~JUNE 30~~MARCH 31 , ~~2021~~202 2 AND ~~2020~~2021			4

UNAUDITED CONSOLIDATED CASH FLOW STATEMENTS FOR THE THREE ~~SIX~~ MONTHS ENDED ~~JUNE~~ MARCH 3 01 , 202 2 AND 2021 ~~AND 2020~~			65
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS			76

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			1513

Item 4. Controls and Procedures			2219

PART II – OTHER INFORMATION			2420



Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			2420

Item 6. Exhibits			2521

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(Unaudited)


		Three Months Ended June 30				Six Months Ended June 30					Three Months Ended March 31
(Millions of dollars, except per share amounts)	(Millions of dollars, except per share amounts)	2021		2020		2021		2020		(Millions of dollars, except per share amounts)	2022		2021
Net Sales	Net Sales	$	4,722	$	4,612	$	9,465	$	9,621	Net Sales	$	5,095	$	4,743
Cost of products sold	Cost of products sold	3,242		2,835		6,396		6,053		Cost of products sold	3,575		3,154
Gross Profit	Gross Profit	1,480		1,777		3,069		3,568		Gross Profit	1,520		1,589
Marketing, research and general expenses	Marketing, research and general expenses	854		844		1,669		1,717		Marketing, research and general expenses	886		815
Other (income) and expense, net	Other (income) and expense, net	13		8		17		22		Other (income) and expense, net	(59)		4
Operating Profit	Operating Profit	613		925		1,383		1,829		Operating Profit	693		770
Nonoperating expense	Nonoperating expense	(55)		(6)		(61)		(17)		Nonoperating expense	(4)		(6)
Interest income	Interest income	2		2		3		4		Interest income	2		1
Interest expense	Interest expense	(65)		(65)		(128)		(126)		Interest expense	(65)		(63)
Income Before Income Taxes and Equity Interests	Income Before Income Taxes and Equity Interests	495		856		1,197		1,690		Income Before Income Taxes and Equity Interests	626		702
Provision for income taxes	Provision for income taxes	(113)		(199)		(260)		(396)		Provision for income taxes	(114)		(147)
Income Before Equity Interests	Income Before Equity Interests	382		657		937		1,294		Income Before Equity Interests	512		555
Share of net income of equity companies	Share of net income of equity companies	28		35		67		73		Share of net income of equity companies	23		39
Net Income	Net Income	410		692		1,004		1,367		Net Income	535		594
Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	(6)		(11)		(16)		(26)		Net income attributable to noncontrolling interests	(12)		(10)
Net Income Attributable to Kimberly-Clark Corporation	Net Income Attributable to Kimberly-Clark Corporation	$	404	$	681	$	988	$	1,341	Net Income Attributable to Kimberly-Clark Corporation	$	523	$	584

Per Share Basis	Per Share Basis									Per Share Basis
Net Income Attributable to Kimberly-Clark Corporation	Net Income Attributable to Kimberly-Clark Corporation									Net Income Attributable to Kimberly-Clark Corporation
Basic	Basic	$	1.20	$	2.00	$	2.92	$	3.93	Basic	$	1.55	$	1.73
Diluted	Diluted	$	1.19	$	1.99	$	2.92	$	3.92	Diluted	$	1.55	$	1.72

See notes to the unaudited interim consolidated financial statements.

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


		Three Months Ended June 30				Six Months Ended June 30					Three Months Ended March 31
(Millions of dollars)	(Millions of dollars)	2021		2020		2021		2020		(Millions of dollars)	2022		2021
Net Income	Net Income	$	410	$	692	$	1,004	$	1,367	Net Income	$	535	$	594
Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax									Other Comprehensive Income (Loss), Net of Tax
Unrealized currency translation adjustments	Unrealized currency translation adjustments	78		125		(137)		(274)		Unrealized currency translation adjustments	53		(215)
Employee postretirement benefits	Employee postretirement benefits	11		5		29		39		Employee postretirement benefits	11		18
Other	Other	22		(24)		58		8		Other	(9)		36
Total Other Comprehensive Income (Loss), Net of Tax	Total Other Comprehensive Income (Loss), Net of Tax	111		106		(50)		(227)		Total Other Comprehensive Income (Loss), Net of Tax	55		(161)
Comprehensive Income	Comprehensive Income	521		798		954		1,140		Comprehensive Income	590		433
Comprehensive (income) loss attributable to noncontrolling interests	Comprehensive (income) loss attributable to noncontrolling interests	(6)		(15)		(9)		(18)		Comprehensive (income) loss attributable to noncontrolling interests	(8)		(3)
Comprehensive Income Attributable to Kimberly-Clark Corporation	Comprehensive Income Attributable to Kimberly-Clark Corporation	$	515	$	783	$	945	$	1,122	Comprehensive Income Attributable to Kimberly-Clark Corporation	$	582	$	430

See notes to the unaudited interim consolidated financial statements.

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(~~2021~~2022 Data is Unaudited)


(Millions of dollars)	(Millions of dollars)	June 30, 2021		December 31, 2020		(Millions of dollars)	March 31, 2022		December 31, 2021
ASSETS	ASSETS					ASSETS
Current Assets	Current Assets					Current Assets
Cash and cash equivalents	Cash and cash equivalents	$	306	$	303	Cash and cash equivalents	$	493	$	270
Accounts receivable, net	Accounts receivable, net	2,340		2,235		Accounts receivable, net	2,516		2,207
Inventories	Inventories	2,110		1,903		Inventories	2,265		2,239
Other current assets	Other current assets	816		733		Other current assets	629		849
Total Current Assets	Total Current Assets	5,572		5,174		Total Current Assets	5,903		5,565
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net	8,018		8,042		Property, Plant and Equipment, Net	8,114		8,097
Investments in Equity Companies	Investments in Equity Companies	350		300		Investments in Equity Companies	266		290
Goodwill	Goodwill	1,834		1,895		Goodwill	2,177		1,840
Other Intangible Assets, Net	Other Intangible Assets, Net	803		832		Other Intangible Assets, Net	926		810
Other Assets	Other Assets	1,250		1,280		Other Assets	1,286		1,235
TOTAL ASSETS	TOTAL ASSETS	$	17,827	$	17,523	TOTAL ASSETS	$	18,672	$	17,837

LIABILITIES AND STOCKHOLDERS' EQUITY	LIABILITIES AND STOCKHOLDERS' EQUITY					LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities	Current Liabilities					Current Liabilities
Debt payable within one year	Debt payable within one year	$	1,493	$	486	Debt payable within one year	$	969	$	433
Trade accounts payable	Trade accounts payable	3,337		3,336		Trade accounts payable	3,846		3,840
Accrued expenses and other current liabilities	Accrued expenses and other current liabilities	2,037		2,262		Accrued expenses and other current liabilities	2,054		2,096
Dividends payable	Dividends payable	377		359		Dividends payable	388		380
Total Current Liabilities	Total Current Liabilities	7,244		6,443		Total Current Liabilities	7,257		6,749
Long-Term Debt	Long-Term Debt	7,591		7,878		Long-Term Debt	8,101		8,141
Noncurrent Employee Benefits	Noncurrent Employee Benefits	875		864		Noncurrent Employee Benefits	797		809
Deferred Income Taxes	Deferred Income Taxes	665		723		Deferred Income Taxes	687		694
Other Liabilities	Other Liabilities	666		718		Other Liabilities	716		681
Redeemable Preferred Securities of Subsidiaries		28		28
Redeemable Common and Preferred Securities of Subsidiaries						Redeemable Common and Preferred Securities of Subsidiaries	260		26
Stockholders' Equity	Stockholders' Equity					Stockholders' Equity
Kimberly-Clark Corporation	Kimberly-Clark Corporation					Kimberly-Clark Corporation
Preferred stock - 0 par value - authorized 20.0 million shares, NaN issued		0		0
Common stock - $1.25 par value - authorized 1.2 billion shares; issued 378.6 million shares at June 30, 2021 and December 31, 2020		473		473
Preferred stock - no par value - authorized 20.0 million shares, none issued						Preferred stock - no par value - authorized 20.0 million shares, none issued	—		—
Common stock - $1.25 par value - authorized 1.2 billion shares; issued 378.6 million shares at March 31, 2022 and December 31, 2021						Common stock - $1.25 par value - authorized 1.2 billion shares; issued 378.6 million shares at March 31, 2022 and December 31, 2021	473		473
Additional paid-in capital	Additional paid-in capital	627		657		Additional paid-in capital	599		605
Common stock held in treasury, at cost - 41.7 and 39.9 million shares at June 30, 2021 and December 31, 2020, respectively		(5,159)		(4,899)
Common stock held in treasury, at cost - 41.6 and 41.8 million shares at March 31, 2022 and December 31, 2021, respectively						Common stock held in treasury, at cost - 41.6 and 41.8 million shares at March 31, 2022 and December 31, 2021, respectively	(5,175)		(5,183)
Retained earnings	Retained earnings	7,798		7,567		Retained earnings	7,988		7,858
Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss)	(3,215)		(3,172)		Accumulated other comprehensive income (loss)	(3,180)		(3,239)
Total Kimberly-Clark Corporation Stockholders' Equity	Total Kimberly-Clark Corporation Stockholders' Equity	524		626		Total Kimberly-Clark Corporation Stockholders' Equity	705		514
Noncontrolling Interests	Noncontrolling Interests	234		243		Noncontrolling Interests	149		223
Total Stockholders' Equity	Total Stockholders' Equity	758		869		Total Stockholders' Equity	854		737
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	17,827	$	17,523	TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	18,672	$	17,837

See notes to the unaudited interim consolidated financial statements.

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(Unaudited)


		Three Months Ended June 30, 2021																																			Three Months Ended March 31, 2022
(Millions of dollars, shares in thousands, except per share amounts)	(Millions of dollars, shares in thousands, except per share amounts)	Common Stock Issued			Additional Paid-in Capital				Treasury Stock						Retained Earnings				Accumulated Other Comprehensive Income (Loss)				Non-controlling Interests					Total Stockholders' Equity						(Millions of dollars, shares in thousands, except per share amounts)			Common Stock Issued						Additional Paid-in Capital				Treasury Stock								Retained Earnings				Accumulated Other Comprehensive Income (Loss)				Non-controlling Interests			Total Stockholders' Equity
		Shares	Amount				Shares			Amount																				(Millions of dollars, shares in thousands, except per share amounts)			Shares				Amount			Additional Paid-in Capital		Shares					Amount					Retained Earnings		Total Stockholders' Equity
Balance at March 31, 2021		378,597	$	473			$	658		40,956			$	(5,050)			$	7,764			$	(3,327)			$	228						$	746
Balance at December 31, 2021																											Balance at December 31, 2021				378,597				$	473		$	605			41,762			$	(5,183)				$	7,858					$	(3,239)				$	223		$	737
Net income in stockholders' equity, excludes redeemable interests' share	Net income in stockholders' equity, excludes redeemable interests' share	—	—		—				—		—				404				—				6					410						Net income in stockholders' equity, excludes redeemable interests' share			—		—				—				—	—							523				—				12			535
Other comprehensive income, net of tax, excludes redeemable interests' share	Other comprehensive income, net of tax, excludes redeemable interests' share	—	—		—				—		—				—				111				—					111						Other comprehensive income, net of tax, excludes redeemable interests' share			—		—				—				—	—							—				59				(4)			55
Stock-based awards exercised or vested	Stock-based awards exercised or vested	—	—		(53)				(637)		70				—				—				—					17						Stock-based awards exercised or vested			—		—				(26)				(347)	35							—				—				—			9
Shares repurchased	Shares repurchased	—	—		—				1,342		(179)				—				—				—					(179)						Shares repurchased			—		—				—				215	(27)							—				—				—			(27)
Recognition of stock-based compensation	Recognition of stock-based compensation	—	—		19				—		—				—				—				—					19						Recognition of stock-based compensation			—		—				16				—	—							—				—				—			16
Dividends declared ($1.14 per share)		—	—		—				—		—				(385)				—				1					(384)
Dividends declared ($1.16 per share)																											Dividends declared ($1.16 per share)				—				—			—			—			—					(391)				—					(82)		(473)
Other	Other	—	—		3				—		—				15				1				(1)					18						Other			—		—				4				—	—							(2)				—				—			2
Balance at June 30, 2021		378,597	$	473	$	627			41,661		$	(5,159)			$	7,798			$	(3,215)			$	234				$	758
Balance at March 31, 2022																											Balance at March 31, 2022				378,597				$	473		$	599		41,630			$	(5,175)				$	7,988			$	(3,180)				$	149	$	854

Six Months Ended June 30, 2021
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at December 31, 2020 378,597 $ 473 $ 657 39,873 $ (4,899) $ 7,567 $ (3,172) $ 243 $ 869
Net income in stockholders' equity, excludes redeemable interests' share — — — — — 988 — 15 1,003
Other comprehensive income, net of tax, excludes redeemable interests' share — — — — — — (43) (7) (50)
Stock-based awards exercised or vested — — (77) (952) 104 — — — 27
Shares repurchased — — — 2,740 (364) — — — (364)
Recognition of stock-based compensation — — 41 — — — — — 41
Dividends declared ($2.28 per share) — — — — — (770) — (17) (787)
Other — — 6 — — 13 — — 19
Balance at June 30, 2021 378,597 $ 473 $ 627 41,661 $ (5,159) $ 7,798 $ (3,215) $ 234 $ 758


	Three Months Ended March 31, 2021
(Millions of dollars, shares in thousands, except per share amounts)	Common Stock Issued			Additional Paid-in Capital		Treasury Stock			Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Non-controlling Interests		Total Stockholders' Equity
	Shares	Amount				Shares	Amount
Balance at December 31, 2020	378,597	$	473	$	657	39,873	$	(4,899)	$	7,567	$	(3,172)	$	243	$	869
Net income in stockholders' equity, excludes redeemable interests' share	—	—		—		—	—		584		—		9		593
Other comprehensive income, net of tax, excludes redeemable interests' share	—	—		—		—	—		—		(154)		(7)		(161)
Stock-based awards exercised or vested	—	—		(24)		(315)	34		—		—		—		10
Shares repurchased	—	—		—		1,398	(185)		—		—		—		(185)
Recognition of stock-based compensation	—	—		22		—	—		—		—		—		22
Dividends declared ($1.14 per share)	—	—		—		—	—		(385)		—		(18)		(403)
Other	—	—		3		—	—		(2)		(1)		1		1
Balance at March 31, 2021	378,597	$	473	$	658	40,956	$	(5,050)	$	7,764	$	(3,327)	$	228	$	746

See notes to the unaudited interim consolidated financial statements.

Three Months Ended June 30, 2020
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at March 31, 2020 378,597 $ 473 $ 559 37,761 $ (4,562) $ 6,978 $ (3,615) $ 213 $ 46
Net income in stockholders' equity, excludes redeemable interests' share — — — — — 681 — 10 691
Other comprehensive income, net of tax, excludes redeemable interests' share — — — — — — 102 4 106
Stock-based awards exercised or vested — — (38) (557) 66 — — — 28
Shares repurchased — — — 370 (49) — — — (49)
Recognition of stock-based compensation — — 38 — — — — — 38
Dividends declared ($1.07 per share) — — — — — (365) — — (365)
Other — — (5) — — 5 — — —
Balance at June 30, 2020 378,597 $ 473 $ 554 37,574 $ (4,545) $ 7,299 $ (3,513) $ 227 $ 495

Six Months Ended June 30, 2020
(Millions of dollars, shares in thousands, except per share amounts) Common Stock
Issued Additional Paid-in Capital Treasury Stock Retained Earnings Accumulated Other Comprehensive Income (Loss) Non-controlling Interests Total Stockholders' Equity
Shares Amount Shares Amount
Balance at December 31, 2019 $ 378.597 $ 473 $ 556 37,149 $ (4,454) $ 6,686 $ (3,294) $ 227 $ 194
Net income in stockholders' equity, excludes redeemable interests' share — — — — — 1,341 — 24 1,365
Other comprehensive income, net of tax, excludes redeemable interests' share — — — — — — (219) (8) (227)
Stock-based awards exercised or vested — — (52) (1,622) 187 — — — 135
Shares repurchased — — — 2,047 (278) — — — (278)
Recognition of stock-based compensation — — 53 — — — — — 53
Dividends declared ($2.14 per share) — — — — — (730) — (17) (747)
Other — — (3) — — 2 — 1 —
Balance at June 30, 2020 378,597 $ 473 $ 554 37,574 $ (4,545) $ 7,299 $ (3,513) $ 227 $ 495

~~See notes to the unaudited interim consolidated financial statements.~~

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

CONSOLIDATED CASH FLOW STATEMENTS

(Unaudited)


		Six Months Ended June 30					Three Months Ended March 31
(Millions of dollars)	(Millions of dollars)	2021		2020		(Millions of dollars)	2022		2021
Operating Activities	Operating Activities					Operating Activities
Net income	Net income	$	1,004	$	1,367	Net income	$	535	$	594
Depreciation and amortization	Depreciation and amortization	378		414		Depreciation and amortization	188		189
Asset impairments	Asset impairments	3		0		Asset impairments	—		3
Gain on previously held equity investment in Thinx						Gain on previously held equity investment in Thinx	(85)		—
Stock-based compensation	Stock-based compensation	42		54		Stock-based compensation	16		22
Deferred income taxes	Deferred income taxes	(74)		12		Deferred income taxes	(52)		(35)
Net (gains) losses on asset dispositions	Net (gains) losses on asset dispositions	15		13		Net (gains) losses on asset dispositions	6		4
Equity companies' earnings (in excess of) less than dividends paid	Equity companies' earnings (in excess of) less than dividends paid	(32)		(47)		Equity companies' earnings (in excess of) less than dividends paid	(23)		(39)
Operating working capital	Operating working capital	(495)		490		Operating working capital	(369)		(400)
Postretirement benefits	Postretirement benefits	36		(15)		Postretirement benefits	(14)		(15)
Other	Other	9		(5)		Other	2		(2)
Cash Provided by Operations	Cash Provided by Operations	886		2,283		Cash Provided by Operations	204		321
Investing Activities	Investing Activities					Investing Activities
Capital spending	Capital spending	(499)		(636)		Capital spending	(253)		(298)
Proceeds from dispositions of property		30		5
Acquisition of business, net of cash acquired						Acquisition of business, net of cash acquired	(34)		—
Investments in time deposits	Investments in time deposits	(451)		(323)		Investments in time deposits	(83)		(159)
Maturities of time deposits	Maturities of time deposits	433		254		Maturities of time deposits	255		207
Other	Other	0		10		Other	(1)		5
Cash Used for Investing	Cash Used for Investing	(487)		(690)		Cash Used for Investing	(116)		(245)
Financing Activities	Financing Activities					Financing Activities
Cash dividends paid	Cash dividends paid	(748)		(722)		Cash dividends paid	(384)		(359)
Change in short-term debt	Change in short-term debt	960		(667)		Change in short-term debt	834		744
Debt proceeds	Debt proceeds	5		1,241		Debt proceeds	—		5
Debt repayments	Debt repayments	(253)		(252)		Debt repayments	(300)		(253)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	27		135		Proceeds from exercise of stock options	23		10
Acquisitions of common stock for the treasury	Acquisitions of common stock for the treasury	(331)		(263)		Acquisitions of common stock for the treasury	(25)		(169)
Other	Other	(54)		(39)		Other	(15)		(30)
Cash Used for Financing	Cash Used for Financing	(394)		(567)		Cash Used for Financing	133		(52)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	Effect of Exchange Rate Changes on Cash and Cash Equivalents	(2)		(20)		Effect of Exchange Rate Changes on Cash and Cash Equivalents	2		(7)
Change in Cash and Cash Equivalents	Change in Cash and Cash Equivalents	3		1,006		Change in Cash and Cash Equivalents	223		17
Cash and Cash Equivalents - Beginning of Period	Cash and Cash Equivalents - Beginning of Period	303		442		Cash and Cash Equivalents - Beginning of Period	270		303
Cash and Cash Equivalents - End of Period	Cash and Cash Equivalents - End of Period	$	306	$	1,448	Cash and Cash Equivalents - End of Period	$	493	$	320

See notes to the unaudited interim consolidated financial statements.

KIMBERLY-CLARK CORPORATION AND SUBSIDIARIES

NOTES TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Accounting Policies

Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all material adjustments which are of a normal and recurring nature necessary for a fair presentation of the results for the periods presented have been reflected. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted.

For further information, refer to the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the year ended December 31, ~~2020.~~2021. The terms "Corporation," "Kimberly-Clark," "K-C," "we," "our" and "us" refer to Kimberly-Clark Corporation and its consolidated subsidiaries.

Highly Inflationary Accounting in Argentina

GAAP guidance requires the use of highly inflationary accounting for countries whose cumulative three-year inflation exceeds 100 percent. In the second quarter of 2018, published inflation indices indicated that the three-year cumulative inflation in Argentina exceeded 100 percent, and as of July 1, 2018, we elected to adopt highly inflationary accounting for our subsidiaries in Argentina (“K-C Argentina”). Under highly inflationary accounting, K-C Argentina’s functional currency became the U.S. dollar, and its income statement and balance sheet have been measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net and was not material. As of ~~June 30, 2021,~~March 31, 2022, K-C Argentina had a small net peso monetary position. Net sales of K-C Argentina were approximately 1 percent of our consolidated net sales for the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 and ~~2020.~~

~~Recently Adopted Accounting Standard~~

~~In 2019, the Financial Accounting Standards Board issued Accounting Standards Update No. 2019-12,~~ ~~Simplifying the Accounting for Income Taxes (Topic 740)~~. The new guidance simplifies the accounting for income taxes by eliminating certain exceptions related to the approach for intraperiod tax allocation, the tax basis of goodwill after a business combination, and the recognition of deferred tax liabilities for outside basis differences. The new guidance also changes the calculation of the income tax impact of hybrid taxes and the methodology for calculating income taxes in an interim period. We adopted this standard as of January 1, 2021 on either a prospective basis or through a modified retrospective approach, as required by the standard. There was no cumulative effect adjustment recorded to retained earnings as the amount was not material. The effects of this standard on our financial position, results of operations and cash flows were not material.2021.

Note 2. ~~2018 Global Restructuring Program~~2022 Acquisition

~~In January 2018,~~On February 24, 2022, we ~~announced~~completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the ~~2018 Global Restructuring Program to reduce our structural cost base by streamlining~~reusable period and simplifying our manufacturing supply chain and overhead organization. We expect to close or sell approximately 10 manufacturing facilities and expand production capacity at several others. We expect to exit or divest some lower-margin businesses that generate approximately 1 percentincontinence underwear category, for total consideration of $181 consisting of cash of $53, the fair value of our previously held equity investment of $127, and certain share-based award costs of $1.

We previously accounted for our ownership interest in Thinx as an equity method investment, but upon increasing our ownership to 58%, we began consolidating the operations of Thinx into our financial statements at the end of the first quarter of 2022. The consolidated results of operations for Thinx are reported in our Personal Care business segment on a one-month lag. The share of Thinx net ~~sales.~~income and equity attributable to the third-party minority owner of Thinx is classified in our consolidated income statement within Net income attributable to noncontrolling interests and in our consolidated balance sheet within Redeemable Common and Preferred Securities of Subsidiaries. This noncontrolling equity interest is measured at the estimated redemption value, which approximates fair value.

We have substantially completed an initial purchase price allocation in which we utilized several generally accepted valuation methodologies to estimate the fair value of certain acquired assets. The ~~restructuring is expected~~primary valuation methods included two forms of the Income Approach (i.e., the multi-period excess earnings method (distributor method) and the relief-from-royalty method). These valuation methodologies are commonly used to ~~impact our organizations in all major geographies. Workforce reductions are expected to be~~value similar identifiable intangible assets in the ~~range~~Consumer Packaged Goods industry. All of ~~6,300~~the selected valuation methodologies incorporate unobservable inputs, or Level 3 inputs, as defined by the fair value hierarchy in Accounting Standard Codification 820, Fair Value Measurements. In connection with these valuation methodologies, we are required to ~~6,400.~~

~~The restructuring is expected~~make estimates and assumptions regarding market comparable companies, revenue growth rates, operating margins, distributor and customer attrition rates, royalty rates, distributor margins, discount rates, etc., which are primarily based on cash flow forecasts, business plans, economic projections and other information available to be completed in 2021, with total costs anticipated to be in the range of $2.0 billion to $2.1 billion pre-tax ($1.5 billion to $1.6 billion after tax). Cash costs are expected to be $1.1 billion to $1.15 billion, primarily related to workforce reductions. Non-cash charges are expected to be $900 to $950 pre-tax and will primarily consist of incremental depreciation, asset write-offs and pension settlement and curtailment charges. Restructuring charges in 2021 are expected to be $180 to $280 pre-tax ($135 to $215 after tax).market participants.

The ~~following~~total purchase price consideration was allocated to the net ~~charges were incurred in connection with the 2018 Global Restructuring Program:~~
Three Months Ended
June 30 Six Months Ended
June 30
2021 2020 2021 2020
Cost of products sold:
Charges (adjustments) for workforce reductions $ 0 $ 1 $ (2) $ 1
Asset impairments 0 0 3 0
Asset write-offs 0 3 1 9
Incremental depreciation 4 33 8 68
Other exit costs 21 23 40 52
Total 25 60 50 130
Marketing, research and general expenses:
Charges (adjustments) for workforce reductions 16 1 14 (2)
Other exit costs 14 26 25 52
Total 30 27 39 50
Other (income) and expense, net 8 0 8 0
Nonoperating expense 56 0 56 0
Total charges 119 87 153 180
Provision for income taxes (25) (15) (32) (33)
Net charges 94 72 121 147
Net impact related to equity companies and noncontrolling interests 0 0 (1) (1)
Net charges attributable to Kimberly-Clark Corporation $ 94 $ 72 $ 120 $ 146
assets acquired based upon their respective estimated fair values as follows:

Current Assets

Property, Plant and Equipment, Net

Goodwill

297

Other Intangible Assets, Net

123

Other Assets

Current Liabilities

(29)

Deferred Income Taxes

(18)

~~The following summarizes the restructuring liabilities activity:~~
2021 2020
Restructuring liabilities at January 1 $ 93 $ 132
Charges for workforce reductions and other cash exit costs 77 99
Cash payments (98) (122)
Currency and other 0 (3)
Restructuring liabilities at June 30 $ 72 $ 106

~~Restructuring liabilities of $57 and $75 are recorded in Accrued expenses and other current liabilities and $15 and $31 are recorded in~~ Other Liabilities

(4)

Fair value of net assets acquired

415

Less fair value of non-controlling interest

(234)

Total purchase price consideration

181

Other Intangible Assets, Net includes brands and customer relationships which have estimated useful lives of 4 to 15 years, primarily 15 years. Based on the carrying value of these finite-lived assets as of ~~June 30, 2021~~March 31, 2022, amortization expense per year for each of the next five years is estimated to be approximately $8.

Goodwill of $297 was allocated to the Personal Care business segment. The goodwill is primarily attributable to future growth opportunities and ~~2020, respectively.~~ any intangible assets that did not qualify for separate recognition. For tax purposes, the acquisition of additional Thinx shares was treated as a stock acquisition, and the goodwill acquired is not tax deductible.

The ~~impact related to restructuring charges is recorded in Operating working capital~~preliminary estimates of the fair value of identifiable assets acquired and ~~Other Operating Activities, as appropriate, in our consolidated cash flow statements.~~

~~Through June 30, 2021, cumulative pre-tax charges for the 2018 Global Restructuring Program were $2.0 billion ($1.5 billion after tax).~~

~~Note 3. 2020 Acquisition~~

~~On October 1, 2020 (“Acquisition Date”), we acquired Softex Indonesia, in an all-cash transaction for approximately $1.2 billion. The transaction price,~~liabilities assumed are subject to ~~working capital and net debt~~revisions, which may result in adjustments ~~resulted in a preliminary purchase price of $1.1 billion as of December 31, 2020 in addition~~ to the ~~assumption of certain indebtedness of Softex Indonesia at closing. The allocation of purchase consideration related to Softex Indonesia was substantially completed in the fourth quarter of 2020.~~ preliminary values discussed above. We continue to evaluate potential contingencies that may have existed as of the acquisition date and expect to finalize the purchase price allocation no later than the ~~fourth~~first quarter of ~~2021.~~2023.

As a result of this transaction during the quarter ended March 31, 2022, an $85 non-recurring, non-cash gain was recognized in Other (income) expense, net as a result of the remeasurement of the carrying value of our previously held equity investment to fair value, and related transaction and integration costs of $21 were recorded in Marketing, research and general expenses. This recognition resulted in a net benefit of $64 pre-tax ($68 after tax) being included in our consolidated income statement for the quarter ended March 31, 2022. In addition, we removed the non-cash gain impact from Operating Activities in our consolidated cash flow statements for the quarter ended March 31, 2022.

~~See Note 3, Acquisition, to~~Pro forma results of operations have not been presented as the impact on our consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 for the preliminary purchase price allocation, valuation methodology, and other information related to the Softex Indonesia acquisition.

is not material.

Note 4.3. Fair Value Information

The following fair value information is based on a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The three levels in the hierarchy used to measure fair value are:

Level 1 – Unadjusted quoted prices in active markets accessible at the reporting date for identical assets and liabilities.

Level 2 – Quoted prices for similar assets or liabilities in active markets. Quoted prices for identical or similar assets and liabilities in markets that are not considered active or financial instruments for which all significant inputs are observable, either directly or indirectly.

Level 3 – Prices or valuations that require inputs that are significant to the valuation and are unobservable.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

During the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 and for the full year ~~2020,~~2021, there were no significant transfers to or from level 3 fair value determinations.

Derivative assets and liabilities are measured on a recurring basis at fair value. At ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, derivative assets were ~~$41~~$57 and ~~$44,~~$65, respectively, and derivative liabilities were ~~$60~~$85 and ~~$92,~~$41, respectively. The fair values of derivatives used to manage interest rate risk and commodity price risk are based on LIBOR rates and interest rate swap curves

and NYMEX price quotations, respectively. The fair values of hedging instruments used to manage foreign currency risk are based on published quotations of spot currency rates and forward points, which are converted into implied forward currency rates. Measurement of our derivative assets and liabilities is considered a level 2 measurement. Additional information on our classification and use of derivative instruments is contained in Note 7.6.

Redeemable common and preferred securities of subsidiaries are measured on a recurring basis at their estimated redemption values, which approximate fair ~~value and were~~ ~~$28~~ asvalue. As of ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, the securities were valued at $260 and $26, respectively. ~~They~~No redeemable common securities were outstanding at December 31, 2021. The securities are not traded in active ~~markets. The fair values of the redeemable securities were based on a discounted cash flow valuation model. Measurement of the redeemable preferred securities~~markets, and their measurement is considered a level 3 measurement.

Company-owned life insurance ("COLI") assets are measured on a recurring basis at fair value. COLI assets were ~~$73~~$69 and $72 at ~~June 30, 2021~~ March 31, 2022 and December 31, ~~2020,~~2021, respectively. The COLI policies are a source of funding primarily for our nonqualified employee benefits and are included in Other Assets. The COLI policies are measured at fair value using the net asset value per share practical expedient, and therefore, are not classified in the fair value hierarchy.

The following table includes the fair value of our financial instruments for which disclosure of fair value is required:


		Fair Value Hierarchy Level		Carrying Amount			Estimated Fair Value			Carrying Amount			Estimated Fair Value			Fair Value Hierarchy Level				Carrying Amount			Estimated Fair Value				Carrying Amount			Estimated Fair Value

			June 30, 2021					December 31, 2020										March 31, 2022						December 31, 2021
Assets	Assets																	Assets
Cash and cash equivalents(a)	Cash and cash equivalents(a)		1		$	306		$	306		$	303		$	303		Cash and cash equivalents(a)		1		$	493			$	493		$	270		$	270
Time deposits(b)	Time deposits(b)	1		369			369			364			364	Time deposits(b)		1				239			239				416			416

Liabilities	Liabilities													Liabilities
Short-term debt(c)	Short-term debt(c)	2		1,180			1,180			223			223	Short-term debt(c)		2				955			955				118			118

Long-term debt(d)	Long-term debt(d)	2		7,904			9,079			8,141			9,627	Long-term debt(d)		2				8,115			8,439				8,456			9,492

(a)Cash equivalents are composed of certificates of deposit, time deposits and other interest-bearing investments with original maturity dates of 90 days or less. Cash equivalents are recorded at cost, which approximates fair value.

(b)Time deposits are composed of deposits with original maturities of more than 90 days but less than one year and instruments with original maturities of greater than one year, included in Other current assets or Other Assets in the consolidated balance sheet, as appropriate. Time deposits are recorded at cost, which approximates fair value.

(c)Short-term debt is composed of U.S. commercial paper and/or other similar short-term debt issued by non-U.S. subsidiaries, all of which are recorded at cost, which approximates fair value.

(d)Long-term debt includes the current portion of these debt instruments. Fair values were estimated based on quoted prices for financial instruments for which all significant inputs were observable, either directly or indirectly.

Note 5.4. Earnings Per Share ("EPS")

There are no adjustments required to be made to net income for purposes of computing EPS. The average number of common shares outstanding is reconciled to those used in the basic and diluted EPS computations as follows:


		Three Months Ended June 30		Six Months Ended June 30			Three Months Ended March 31
(Millions of shares)	(Millions of shares)	2021	2020	2021	2020	(Millions of shares)	2022	2021
Basic	Basic	337.3	340.9	337.8	341.1	Basic	337.0	338.2
Dilutive effect of stock options and restricted share unit awards	Dilutive effect of stock options and restricted share unit awards	1.0	1.0	1.0	1.2	Dilutive effect of stock options and restricted share unit awards	1.2	1.2
Diluted	Diluted	338.3	341.9	338.8	342.3	Diluted	338.2	339.4

The impact of options outstanding that were not included in the computation of diluted EPS because their exercise price was greater than the average market price of the common shares was insignificant. The number of common shares outstanding as of ~~June 30,~~March 31, 2022 and 2021 ~~and 2020~~ was ~~336.9~~337.0 million and ~~341.0~~337.6 million, respectively.

Note 6.5. Stockholders' Equity

Net unrealized currency gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries, except those in highly inflationary economies, are recorded in Accumulated Other Comprehensive Income ("AOCI"). For these operations, changes in exchange rates generally do not affect cash flows; therefore, unrealized translation adjustments are recorded in AOCI rather than net income. Upon sale or substantially complete liquidation of any of these subsidiaries, the

applicable unrealized translation would be removed from AOCI and reported as part of the gain or loss on the sale or liquidation.

Also included in unrealized translation amounts are the effects of foreign exchange rate changes on intercompany balances of a long-term investment nature and transactions designated as hedges of net foreign investments.

The change in net unrealized currency translation for the ~~six~~three months ended ~~June 30, 2021~~March 31, 2022 was primarily due to the ~~weakening~~strengthening of certain foreign currencies versus the U.S. dollar, particularly the ~~Indonesian rupiah, the Korean won and the euro.~~Brazilian real.

The changes in the components of AOCI attributable to Kimberly-Clark, net of tax, are as follows:


		Unrealized Translation		Defined Benefit Pension Plans			Other Postretirement Benefit Plans			Cash Flow Hedges and Other
Balance as of December 31, 2019		$	(2,271)	$	(979)		$	(13)		$	(31)
Other comprehensive income (loss) before reclassifications		(266)		22			2			17
(Income) loss reclassified from AOCI		0		16		(a)	(1)		(a)	(9)
Net current period other comprehensive income (loss)		(266)		38			1			8

Balance as of June 30, 2020		$	(2,537)	$	(941)		$	(12)		$	(23)
													Unrealized Translation		Defined Benefit Pension Plans			Other Postretirement Benefit Plans			Cash Flow Hedges and Other
Balance as of December 31, 2020	Balance as of December 31, 2020	$	(2,157)	$	(912)		$	(40)		$	(63)	Balance as of December 31, 2020	$	(2,157)	$	(912)		$	(40)		$	(63)
Other comprehensive income (loss) before reclassifications	Other comprehensive income (loss) before reclassifications	(127)		1			(12)			28		Other comprehensive income (loss) before reclassifications	(205)		—			2			22
(Income) loss reclassified from AOCI	(Income) loss reclassified from AOCI	0		38		(a)	0		(a)	29		(Income) loss reclassified from AOCI	—		14		(a)	—		(a)	12
Net current period other comprehensive income (loss)	Net current period other comprehensive income (loss)	(127)		39			(12)			57		Net current period other comprehensive income (loss)	(205)		14			2			34

Balance as of June 30, 2021		$	(2,284)	$	(873)		$	(52)		$	(6)
Balance as of March 31, 2021												Balance as of March 31, 2021	$	(2,362)	$	(898)		$	(38)		$	(29)

Balance as of December 31, 2021												Balance as of December 31, 2021	$	(2,422)	$	(803)		$	(34)		$	20
Other comprehensive income (loss) before reclassifications												Other comprehensive income (loss) before reclassifications	57		7			(2)			(2)
(Income) loss reclassified from AOCI												(Income) loss reclassified from AOCI	—		6		(a)	—		(a)	(7)
Net current period other comprehensive income (loss)												Net current period other comprehensive income (loss)	57		13			(2)			(9)

Balance as of March 31, 2022												Balance as of March 31, 2022	$	(2,365)	$	(790)		$	(36)		$	11

(a) Included in computation of net periodic benefit costs.

Note 7.6. Objectives and Strategies for Using Derivatives

As a multinational enterprise, we are exposed to financial risks, such as changes in foreign currency exchange rates, interest ~~rates,~~rates, and commodity prices. We employ a number of practices to manage these risks, including operating and financing activities and, where appropriate, the use of derivative instruments.

At ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, derivative assets were ~~$41~~$57 and ~~$44,~~$65, respectively, and derivative liabilities were ~~$60~~$85 and ~~$92,~~$41, respectively, primarily comprised of foreign currency exchange contracts. Derivative assets are recorded in Other

current assets or Other Assets, as appropriate, and derivative liabilities are recorded in Accrued expenses and other current liabilities or Other Liabilities, as appropriate.

Foreign Currency Exchange Rate Risk

Translation adjustments result from translating foreign entities' financial statements into U.S. dollars from their functional currencies. The risk to any particular entity's net assets is reduced to the extent that the entity is financed with local currency borrowings. A portion of our balance sheet translation exposure for certain affiliates, which results from changes in translation rates between the affiliates’ functional currencies and the U.S. dollar, is hedged with cross-currency swap contracts and certain foreign denominated debt which are designated as net investment hedges. The foreign currency exposure on certain non-functional currency denominated monetary assets and liabilities, primarily intercompany loans and accounts payable, is hedged with primarily undesignated derivative instruments.

Derivative instruments are entered into to hedge a portion of forecasted cash flows denominated in foreign currencies for non-U.S. operations' purchases of raw materials, which are priced in U.S. dollars, and imports of intercompany finished goods and work-in-process priced predominantly in U.S. dollars and euros. The derivative instruments used to manage these exposures are designated as cash flow hedges.

Interest Rate Risk

Interest rate risk is managed using a portfolio of variable and fixed-rate debt composed of short and long-term instruments. Interest rate swap contracts may be used to facilitate the maintenance of the desired ratio of variable and fixed-rate debt and are designated as fair value hedges. From time to time, we also hedge the anticipated issuance of fixed-rate debt, and these contracts are designated as cash flow hedges.

Commodity Price Risk

We use derivative instruments, such as forward contracts, to hedge a limited portion of our exposure to market risk arising from changes in prices of certain commodities. These derivatives are designated as cash flow hedges of specific quantities of the underlying commodity expected to be purchased in future months. In addition, we utilize negotiated ~~short-term contract structures, including fixed price~~ contracts of varying durations along with strategic pricing mechanisms to manage volatility for a portion of our commodity costs.

Fair Value Hedges

Derivative instruments that are designated and qualify as fair value hedges are predominantly used to manage interest rate risk. The fair values of these interest rate derivative instruments are recorded as an asset or liability, as appropriate, with the offset recorded in Interest expense. The offset to the change in fair values of the related debt is also recorded in Interest expense. Any realized gain or loss on the derivatives that hedge interest rate risk is amortized to Interest expense over the life of the related debt. As of ~~June 30, 2021,~~March 31, 2022, the aggregate notional values and carrying values of debt subject to outstanding interest rate contracts designated as fair value hedges were ~~$625~~$525 and ~~$642,~~$501, respectively. For the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ gains or losses recognized in Interest expense for interest rate swaps were not significant.

Cash Flow Hedges

For derivative instruments that are designated and qualify as cash flow hedges, the gain or loss on the derivative instrument is initially recorded in AOCI, net of related income taxes, and recognized in earnings in the same income statement line and period that the hedged exposure affects earnings. As of ~~June 30, 2021,~~March 31, 2022, outstanding commodity forward contracts were in place to hedge a limited portion of our estimated requirements of the related underlying commodities in the remainder of ~~2021~~2022 and future periods. As of ~~June 30, 2021,~~March 31, 2022, the aggregate notional value of outstanding foreign exchange derivative contracts designated as cash flow hedges was ~~$741.~~$781. For the ~~six~~three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ no significant gains or losses were reclassified into Interest expense, Cost of products sold or Other (income) and expense, net as a result of the discontinuance of cash flow hedges due to the original forecasted transaction no longer being probable of occurring. At ~~June 30, 2021,~~March 31, 2022, amounts to be reclassified from AOCI into Interest expense, Cost of products sold or Other (income) and expense, net during the next twelve months are not expected to be material. The maximum maturity of cash flow hedges in place at ~~June 30, 2021~~March 31, 2022 is ~~June 2023.~~December 2024.

Net Investment Hedges

For derivative instruments that are designated and qualify as net investment hedges, the aggregate notional value was ~~1.5~~$1.4 billion at ~~June 30, 2021.~~March 31, 2022. We exclude the interest accruals on cross-currency swap contracts and the forward points on foreign exchange forward contracts from the assessment and measurement of hedge effectiveness. We recognize the interest accruals on cross-currency swap contracts in earnings within Interest expense. We amortize the forward points on foreign exchange contracts into earnings within Interest expense over the life of the hedging relationship. Changes in fair value of net investment hedges are recorded in AOCI and offset the change in the value of the net investment being hedged. For the ~~six~~three months ended

~~June 30, 2021,~~ March 31, 2022, unrealized gains of ~~$25~~$9 related to net investment hedge fair value changes were recorded in AOCI and no significant amounts were reclassified from AOCI to Interest expense.

No significant amounts were excluded from the assessment of net investment, fair value or cash flow hedge effectiveness as of ~~June 30, 2021.~~March 31, 2022.

Undesignated Hedging Instruments

Gains or losses on undesignated foreign exchange hedging instruments are immediately recognized in Other (income) and expense, net. ~~Gains~~A loss of $3$34 and ~~$12~~a loss of $9 were recorded in the three months ended ~~June 30,~~March 31, 2022 and 2021, ~~and 2020,~~ respectively. ~~A loss of $6 and gain of $8 were recorded in the six months ended June 30, 2021 and 2020.~~ The effect on earnings from the use of these non-designated derivatives is substantially neutralized by the transactional gains and losses recorded on the underlying assets and liabilities. At ~~June 30, 2021,~~March 31, 2022, the notional value of these undesignated derivative instruments was approximately ~~$2.3 billion.~~$2.2 billion.

Note 8.7. Business Segment Information

We are organized into operating segments based on product groupings. These operating segments have been aggregated into three reportable global business segments: Personal Care, Consumer Tissue and K-C Professional. The reportable segments were determined in accordance with how our chief operating decision maker and our executive managers develop and execute global strategies to drive growth and profitability. These strategies include global plans for branding and product positioning, technology, research and development programs, cost reductions including supply chain management, and capacity and capital investments for each of these businesses. Segment management is evaluated on several factors, including operating profit. Segment operating profit excludes Other (income) and expense, net and income and expense not associated with ongoing

operations of the business segments, including the costs of corporate decisions related to the 2018 Global Restructuring Program ~~described~~which was completed in ~~Note 2.~~2021.

The principal sources of revenue in each global business segment are described below:

•Personal Care brands offer our consumers a trusted partner in caring for themselves and their families by delivering confidence, protection and discretion through a wide variety of innovative solutions and products such as disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products. Products in this segment are sold under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise and other brand names.

•Consumer Tissue offers a wide variety of innovative solutions and trusted brands that responsibly improve everyday living for families around the world. Products in this segment include facial and bathroom tissue, paper towels, napkins and related products, and are sold under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve and other brand names.

•K-C Professional partners with businesses to create Exceptional Workplaces, helping to make them healthier, safer and more productive through a range of solutions and supporting products such as wipers, tissue, towels, apparel, soaps and sanitizers. Our brands, including Kleenex, Scott, WypAll, Kimtech and KleenGuard are well known for quality and trusted to help people around the world work better.

Information concerning consolidated operations by business segment is presented in the following tables:


		Three Months Ended June 30						Six Months Ended June 30							Three Months Ended March 31
		2021		2020		Change		2021		2020		Change			2022		2021		Change
NET SALES	NET SALES													NET SALES
Personal Care	Personal Care	$	2,517	$	2,229	+13	%	$	4,979	$	4,651	+7	%	Personal Care	$	2,729	$	2,462	+11	%
Consumer Tissue	Consumer Tissue	1,424		1,645		-13	%	2,934		3,368		-13	%	Consumer Tissue	1,568		1,510		+4	%
K-C Professional	K-C Professional	765		724		+6	%	1,517		1,572		-3	%	K-C Professional	780		752		+4	%
Corporate & Other	Corporate & Other	16		14		N.M.		35		30		N.M.		Corporate & Other	18		19		N.M.
TOTAL NET SALES	TOTAL NET SALES	$	4,722	$	4,612	+2	%	$	9,465	$	9,621	-2	%	TOTAL NET SALES	$	5,095	$	4,743	+7	%

OPERATING PROFIT	OPERATING PROFIT													OPERATING PROFIT
Personal Care	Personal Care	$	454	$	519	-13	%	$	935	$	1,046	-11	%	Personal Care	$	475	$	481	-1	%
Consumer Tissue	Consumer Tissue	196		428		-54	%	465		793		-41	%	Consumer Tissue	171		269		-36	%
K-C Professional	K-C Professional	110		155		-29	%	236		336		-30	%	K-C Professional	90		126		-29	%
Corporate & Other(a)	Corporate & Other(a)	(134)		(169)		N.M.		(236)		(324)		N.M.		Corporate & Other(a)	(102)		(102)		N.M.
Other (income) and expense, net(a)	Other (income) and expense, net(a)	13		8		+63	%	17		22		-23	%	Other (income) and expense, net(a)	(59)		4		N.M.
TOTAL OPERATING PROFIT	TOTAL OPERATING PROFIT	$	613	$	925	-34	%	$	1,383	$	1,829	-24	%	TOTAL OPERATING PROFIT	$	693	$	770	-10	%

(a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including the non-cash, non-recurring gain and transaction and integration costs related to the acquisition of a controlling interest in Thinx in 2022 and charges related to the 2018 Global Restructuring ~~Program.~~ Program in 2021. Restructuring charges related to the Personal Care, Consumer Tissue and K-C Professional ~~business segments were~~ ~~$24, $26 and $6, respectively,~~ for the three months ended ~~June 30,~~March 31, 2021 ~~$40, $34,~~were, $15, $16, and $11, respectively, for the three months ended June 30, 2020, $39, $42 and $9, respectively, for the six months ended June 30, 2021, and $74, $76 and $26, respectively for the six months ended June 30, 2020 .$3, respectively.

N.M. - Not Meaningful

Sales of Principal Products:


		Three Months Ended June 30				Six Months Ended June 30					Three Months Ended March 31
(Billions of dollars)	(Billions of dollars)	2021		2020		2021		2020		(Billions of dollars)	2022		2021
Baby and child care products	Baby and child care products	1.8		1.5		3.5		3.2		Baby and child care products	$	1.9	$	1.7
Consumer tissue products	Consumer tissue products	1.4		1.6		2.9		3.4		Consumer tissue products	1.6		1.5
Away-from-home professional products	Away-from-home professional products	0.8		0.7		1.5		1.6		Away-from-home professional products	0.8		0.8
All other	All other	0.7		0.8		1.6		1.4		All other	0.8		0.7
Consolidated	Consolidated	$	4.7	$	4.6	$	9.5	$	9.6	Consolidated	$	5.1	$	4.7

Note 9.8. Supplemental Balance Sheet Data

The following schedule presents a summary of inventories by major class:


		June 30, 2021						December 31, 2020							March 31, 2022						December 31, 2021
		LIFO		Non-LIFO		Total		LIFO		Non-LIFO		Total			LIFO		Non-LIFO		Total		LIFO		Non-LIFO		Total
Raw materials	Raw materials	$	141	$	301	$	442	$	131	$	263	$	394	Raw materials	$	152	$	362	$	514	$	141	$	352	$	493
Work in process	Work in process	149		86		235		103		86		189		Work in process	153		96		249		153		89		242
Finished goods	Finished goods	585		769		1,354		453		749		1,202		Finished goods	621		817		1,438		607		835		1,442
Supplies and other	Supplies and other	0		276		276		0		263		263		Supplies and other	—		290		290		—		280		280
		875		1,432		2,307		687		1,361		2,048			926		1,565		2,491		901		1,556		2,457
Excess of FIFO or weighted-average cost over LIFO cost	Excess of FIFO or weighted-average cost over LIFO cost	(197)		0		(197)		(145)		0		(145)		Excess of FIFO or weighted-average cost over LIFO cost	(226)		—		(226)		(218)		—		(218)
Total	Total	$	678	$	1,432	$	2,110	$	542	$	1,361	$	1,903	Total	$	700	$	1,565	$	2,265	$	683	$	1,556	$	2,239

Inventories are valued at the lower of cost or net realizable value, determined on the FIFO or weighted-average cost methods, and at the lower of cost or market, determined on the LIFO cost method.

The following schedule presents a summary of property, plant and equipment, net:


		June 30, 2021		December 31, 2020			March 31, 2022		December 31, 2021
Land	Land	$	171	$	174	Land	$	168	$	169
Buildings	Buildings	2,991		2,932		Buildings	3,026		2,993
Machinery and equipment	Machinery and equipment	14,668		14,382		Machinery and equipment	14,745		14,606
Construction in progress	Construction in progress	633		845		Construction in progress	766		760
		18,463		18,333			18,705		18,528
Less accumulated depreciation	Less accumulated depreciation	(10,445)		(10,291)		Less accumulated depreciation	(10,591)		(10,431)
Total	Total	$	8,018	$	8,042	Total	$	8,114	$	8,097

1412

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Introduction

This management's discussion and analysis ("MD&A") of financial condition and results of operations is intended to provide investors with an understanding of our recent performance, financial condition and prospects. Dollar amounts are reported in millions, except per share dollar amounts, unless otherwise noted. The following will be discussed and analyzed:

•Overview of ~~Second~~First Quarter ~~2021~~2022 Results

•~~Impact of COVID-19~~

•Results of Operations and Related Information

•Liquidity and Capital Resources

•Information Concerning Forward-Looking Statements

We describe our business outside North America in two groups – Developing and Emerging Markets ("D&E") and Developed Markets. D&E markets comprise Eastern Europe, the Middle East and Africa, Latin America and Asia-Pacific, excluding Australia and South Korea. Developed Markets consist of Western and Central Europe, Australia and South Korea. We have three reportable business segments: Personal Care, Consumer Tissue and K-C Professional. These business segments are described in greater detail in Note 87 to the unaudited interim consolidated financial statements.

On February 24, 2022, we completed our acquisition of a majority and controlling share of Thinx Inc. (“Thinx”), an industry leader in the reusable period and incontinence underwear category, for total consideration of $181 consisting of cash of $53, the fair value of our previously held equity investment of $127, and certain share-based award costs of $1.

This section presents a discussion and analysis of our ~~second~~first quarter ~~2021~~2022 net sales, operating profit and other information relevant to an understanding of the results of operations. In addition, we provide commentary regarding organic sales growth, which describes the impact of changes in volume, net selling prices and product mix on net sales. Change in foreign currency exchange rates ~~acquisitions~~ and exited businesses also impact the year-over-year change in net sales. Our analysis compares the three ~~and six~~ months ended ~~June 30, 2021~~March 31, 2022 results to the same ~~periods~~period in ~~2020.~~2021.

In March 2022, we implemented significant adjustments to our business in Russia and suspended all media, advertising and promotional activity as well as capital investments in our sole manufacturing facility. Consistent with the humanitarian nature of our products, we are producing only essential items, specifically baby diapers and feminine pads, which are critical to the health and hygiene of women, girls and babies, but our ability to provide these items may change as the situation evolves. Our Russia business has historically represented approximately 1 to 2 percent of our net sales, operating profit and total assets. We are actively monitoring the situation, and as the business, geopolitical and regulatory environment concerning Russia evolves, our assets may be partially or fully impaired. For a more complete discussion of the risks we encounter in our business, please refer to Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021.

Throughout this MD&A, we refer to financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures. These measures include adjusted gross and operating profit, adjusted net income, adjusted earnings per share, adjusted other (income) and expense, net and adjusted effective tax rate. We believe these measures provide our investors with additional information about our underlying results and trends, as well as insight into some of the financial measures used to evaluate management.

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with our unaudited interim consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. We compensate for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures.

The non-GAAP financial measures exclude the following item for the relevant time ~~periods~~period as indicated in the reconciliations included later in this MD&A:

•Acquisition of controlling interest in Thinx – In the first quarter of 2022, we increased our investment in Thinx. As a result of this transaction, a net benefit was recognized of $64 pre-tax ($68 after tax), primarily due to the non-recurring, non-cash gain recognized related to the remeasurement of the carrying value of our previously held equity investment to fair value partially offset by transaction and integration costs. See Item 1, Note 2 to the unaudited interim consolidated financial statements for details.

The non-GAAP financial measures also exclude charges in 2021 for the 2018 Global Restructuring Program -as indicated in the reconciliations included later in this MD&A. In 2018, we initiated this restructuring ~~program~~in order to reduce our structural cost base by streamlining and simplifying our manufacturing supply chain and overhead organization. ~~See Item 1, Note 2 to the unaudited interim consolidated financial statements~~As a result, we recognized restructuring charges in 2018, 2019, 2020 and 2021 for ~~details.~~this program. Restructuring actions were completed in 2021.

Overview of ~~Second~~First Quarter ~~2021~~2022 Results

•Net sales of ~~$4.7~~$5.1 billion increased 27 percent compared to the year-ago period, including an organic sales ~~decline~~growth of 310 percent.

•Operating profit was ~~$613~~$693 in ~~2021~~2022 and ~~$925~~$770 in ~~2020.~~2021. Net Income Attributable to Kimberly-Clark Corporation was ~~$404~~$523 in ~~2021~~2022 compared to ~~$681~~$584 in ~~2020,~~2021, and diluted earnings per share were ~~$1.19~~$1.55 in ~~2021~~2022 compared to ~~$1.99~~$1.72 in ~~2020.~~2021. Results in 2022 include the net benefit of the acquisition of a controlling interest of Thinx, compared to 2021 ~~and 2020~~results, which include charges related to the 2018 Global Restructuring Program.

~~Impact of COVID-19~~

We continue to actively address the COVID-19 situation and its impact globally. We believe that we will emerge from these events well positioned for long-term growth, though we cannot reasonably estimate the duration and severity of this global pandemic or its ultimate impact on the global economy and our business and results.

We have experienced increased volatility in demand for some of our products as consumers adapt to the evolving environment. Throughout 2020 demand increased in our Consumer Tissue and Personal Care business segments across all major geographies as consumers increased home inventory levels in response to COVID-19. Elevated sales were particularly pronounced in our Consumer Tissue business, with a second spike during the fourth quarter as COVID-19 cases surged in advance of the winter season. The demand increase was followed by a period of retail demand softness in the first six months of 2021 as consumers used existing home inventories. Our K-C Professional business experienced volume declines throughout 2020 and the first six months of 2021 reflecting the reduction in away from home demand.

During 2020 and to a more limited extent the first six months of 2021, we experienced temporary closures of certain facilities, though we did not experience a material impact from a plant closure and our facilities were largely exempt or partially exempt from government closure orders. At many of our facilities, we have been experiencing increased employee absences, which may continue in the current situation. We have also experienced incidents of supply chain disruption and raw material shortages, particularly in markets where COVID-19 case levels have spiked.

During 2020 and the first six months of 2021, we also experienced increased volatility in foreign currency exchange rates and commodity prices (including substantial commodity inflation in the first six months of 2021), as certain countries experienced increased macro-economic volatility from the COVID-19 situation.

Results of Operations and Related Information

Consolidated


Selected Financial Results	Selected Financial Results	Three Months Ended June 30						Six Months Ended June 30						Selected Financial Results	Three Months Ended March 31
		2021		2020		Percent Change		2021		2020		Percent Change			2022		2021		Percent Change
Net Sales:	Net Sales:													Net Sales:
North America	North America	$	2,393	$	2,623	-9	%	$	4,744	$	5,224	-9	%	North America	$	2,614	$	2,351	+11	%
Outside North America	Outside North America	2,405		2,052		+17	%	4,875		4,536		+7	%	Outside North America	2,546		2,470		+3	%
Intergeographic sales	Intergeographic sales	(76)		(63)		+21	%	(154)		(139)		+11	%	Intergeographic sales	(65)		(78)		-17	%
Total Net Sales	Total Net Sales	4,722		4,612		+2	%	9,465		9,621		-2	%	Total Net Sales	5,095		4,743		+7	%
Operating Profit:	Operating Profit:													Operating Profit:
North America	North America	488		769		-37	%	997		1,428		-30	%	North America	459		508		-10	%
Outside North America	Outside North America	272		333		-18	%	639		747		-14	%	Outside North America	277		367		-25	%
Corporate & Other(a)	Corporate & Other(a)	(134)		(169)		N.M.		(236)		(324)		N.M.		Corporate & Other(a)	(102)		(101)		N.M.
Other (income) and expense, net(a)	Other (income) and expense, net(a)	13		8		+63	%	17		22		-23	%	Other (income) and expense, net(a)	(59)		4		N.M.
Total Operating Profit	Total Operating Profit	613		925		-34	%	1,383		1,829		-24	%	Total Operating Profit	693		770		-10	%

Share of net income of equity companies	Share of net income of equity companies	28		35		-20	%	67		73		-8	%	Share of net income of equity companies	23		39		-41	%

Net Income Attributable to Kimberly-Clark Corporation	Net Income Attributable to Kimberly-Clark Corporation	404		681		-41	%	988		1,341		-26	%	Net Income Attributable to Kimberly-Clark Corporation	523		584		-10	%
Diluted Earnings per Share	Diluted Earnings per Share	1.19		1.99		-40	%	2.92		3.92		-26	%	Diluted Earnings per Share	1.55		1.72		-10	%

(a) Corporate & Other and Other (income) and expense, net include income and expense not associated with the business segments, including adjustments as indicated in the Non-GAAP Reconciliations.

N.M. - Not Meaningful

1614

GAAP to Non-GAAP Reconciliations of Selected Financial Results


		Three Months Ended June 30, 2021							Three Months Ended March 31, 2022
		As Reported			2018 Global Restructuring Program		As Adjusted Non-GAAP				As Reported			Acquisition of Controlling Interest in Thinx		As Adjusted Non-GAAP
Cost of products sold		$	3,242		$	25	$	3,217
Gross Profit		1,480			(25)		1,505

Marketing, research and general expenses	Marketing, research and general expenses	854			30		824			Marketing, research and general expenses	$	886		$	21	$	865
Other (income) and expense, net	Other (income) and expense, net	13			8		5			Other (income) and expense, net	(59)			(85)		26
Operating Profit	Operating Profit	613			(63)		676			Operating Profit	693			64		629
Nonoperating expense		(55)			(56)		1

Provision for income taxes	Provision for income taxes	(113)			25		(138)			Provision for income taxes	(114)			4		(118)
Effective tax rate	Effective tax rate	22.8		%	—		22.5		%	Effective tax rate	18.2		%	—		21.0		%

Net Income Attributable to Kimberly-Clark Corporation	Net Income Attributable to Kimberly-Clark Corporation	404			(94)		498			Net Income Attributable to Kimberly-Clark Corporation	523			68		455
Diluted Earnings per Share(a)	Diluted Earnings per Share(a)	1.19			(0.28)		1.47			Diluted Earnings per Share(a)	1.55			0.20		1.35

Three Months Ended June 30, 2020
As
Reported 2018 Global
Restructuring
Program As
Adjusted
Non-GAAP
Cost of products sold $ 2,835 $ 60 $ 2,775
Gross Profit 1,777 (60) 1,837
Marketing, research and general expenses 844 27 817
Operating Profit 925 (87) 1,012
Provision for income taxes (199) 15 (214)
Effective tax rate 23.2 % — 22.7 %
Share of net income of equity companies 35 (1) 36
Net income attributable to noncontrolling interests (11) 1 (12)
Net Income Attributable to Kimberly-Clark Corporation 681 (72) 753
Diluted Earnings per Share(a)
1.99 (0.21) 2.20

Six Months Ended June 30, 2021
As
Reported 2018 Global
Restructuring
Program As
Adjusted
Non-GAAP
Cost of products sold $ 6,396 $ 50 $ 6,346
Gross profit 3,069 (50) 3,119
Marketing, research and general expenses 1,669 39 1,630
Other (income) and expense, net 17 8 9
Operating profit 1,383 (97) 1,480
Nonoperating expense (61) (56) (5)
Provision for income taxes (260) 32 (292)
Effective tax rate 21.7 % — 21.6 %
Net income attributable to noncontrolling interests (16) 1 (17)
Net income attributable to Kimberly‑Clark Corporation 988 (120) 1,108
Diluted earnings per share(a)
2.92 (0.35) 3.27


		Six Months Ended June 30, 2020									Three Months Ended March 31, 2021
		As Reported			2018 Global Restructuring Program		As Adjusted Non-GAAP				As Reported			2018 Global Restructuring Program		As Adjusted Non-GAAP
Cost of products sold	Cost of products sold	$	6,053		$	130	$	5,923		Cost of products sold	$	3,154		$	25	$	3,129
Gross profit		3,568			(130)		3,698
Gross Profit										Gross Profit	1,589			(25)		1,614
Marketing, research and general expenses	Marketing, research and general expenses	1,717			50		1,667			Marketing, research and general expenses	815			9		806

Operating profit		1,829			(180)		2,009
Operating Profit										Operating Profit	770			(34)		804

Provision for income taxes	Provision for income taxes	(396)			33		(429)			Provision for income taxes	(147)			7		(154)
Effective tax rate	Effective tax rate	23.4		%	—		22.9		%	Effective tax rate	20.9		%	—		20.9		%
Share of net income of equity companies		73			(1)		74

Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	(26)			2		(28)			Net income attributable to noncontrolling interests	(10)			1		(11)
Net income attributable to Kimberly-Clark Corporation		1,341			(146)		1,487
Net Income Attributable to Kimberly-Clark Corporation										Net Income Attributable to Kimberly-Clark Corporation	584			(26)		610
Diluted Earnings per Share(a)	Diluted Earnings per Share(a)	3.92			(0.43)		4.34			Diluted Earnings per Share(a)	1.72			(0.08)		1.80

(a) "As Adjusted Non-GAAP" may not equal "As Reported" plus "Adjustments" as a result of rounding.

Analysis of Consolidated Results


Net Sales	Net Sales	Percent Change		Adjusted Operating Profit	Percent Change		Net Sales	Percent Change for Three Months Ended March 31, 2022	Adjusted Operating Profit	Percent Change for Three Months Ended March 31, 2022
		Three Months Ended June 30	Six Months Ended June 30		Three Months Ended June 30	Six Months Ended June 30
Volume	Volume	(4)	(7)	Volume	(15)	(18)	Volume	2	Volume	(2)
Net Price	Net Price	1	1	Net Price	3	4	Net Price	6	Net Price	37
Mix/Other	Mix/Other	1	1	Input Costs	(34)	(24)	Mix/Other	2	Input Costs	(58)
Acquisition/Exited Businesses(e)		2	2	Cost Savings(c)	14	13
Currency	Currency	3	2	Currency Translation	2	2	Currency	(2)	Cost Savings(c)	6
Total(a)	Total(a)	2	(2)	Other(d)	(3)	(3)	Total(a)	7	Currency Translation	(2)
									Other(d)	(3)
Organic(b)	Organic(b)	(3)	(5)	Total	(33)	(26)	Organic(b)	10	Total	(22)

(a) Total may not equal the sum of volume, net price, mix/other ~~acquisition/exited businesses~~ and currency due to rounding.

(b) Combined impact of changes in volume, net price and mix/other.

(c) ~~Combined benefits~~Benefits of the FORCE (Focused On Reducing Costs Everywhere) ~~program and 2018 Global Restructuring Program.~~program.

(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.

~~(e)~~ ~~Combined impact of the acquisition of Softex Indonesia and exited businesses in conjunction with the 2018 Global Restructuring Program.~~

Net sales in the ~~second~~first quarter of ~~$4.7~~$5.1 billion increased 27 percent compared to the ~~year ago~~year-ago period. Changes in foreign currency exchange rates ~~increased sales by 3 percent and the net impact of the Softex Indonesia acquisition and exited businesses in conjunction with the 2018 Global Restructuring Program increased~~reduced sales by 2 percent. Organic sales ~~decreased 3~~increased 10 percent as ~~volumes declined 4 percent while the combined impact of~~ changes in net selling prices increased sales by 6 percent, volumes grew 2 percent and changes in product mix increased sales by ~~approximately 1~~2 percent.

In North America, organic sales ~~decreased 11~~increased 13 percent in consumer products and 4increased 5 percent in K-C Professional. Volumes in North America, particularly consumer tissue, were negatively impacted by consumer and retailer destocking following the stock up that occurred in prior periods related to the global outbreak of COVID-19. Outside North America, organic sales ~~were up 9~~rose 10 percent in D&E markets and ~~up 1~~8 percent in developed markets.

Operating profit in the ~~second~~first quarter was ~~$613~~$693 in ~~2021~~2022 and ~~$925~~$770 in ~~2020.~~ 2021.Results in ~~both periods~~2022 include the net benefit of the acquisition of a controlling interest in Thinx, compared to 2021 results which include charges related to the 2018 Global

Restructuring Program. ~~Second~~First quarter adjusted operating profit was ~~$676~~$629 in ~~2021~~2022 and ~~$1,012~~$804 in ~~2020.~~ 2021.Results were impacted by ~~lower sales volumes and $345~~$470 of higher input costs, driven by pulp ~~other~~and polymer-based materials, distribution and ~~distribution~~energy costs. ~~Other manufacturing costs were higher, including inefficiencies from lower production volumes.~~ Higher marketing, research and general expense as well as the impact of unfavorable foreign currency transaction effects reduced operating profit in the quarter. Results benefited from ~~higher net selling prices, $115~~organic sales growth, $50 of cost savings from our FORCE program ~~$30 of cost savings from the 2018 Global Restructuring Program~~ and lower ~~marketing, research and general expense.~~

other manufacturing costs.

The ~~second~~first quarter effective tax rate was ~~22.8~~18.2 percent in ~~2021~~2022 and ~~23.2~~20.9 percent in ~~2020.~~2021. The ~~second~~first quarter adjusted effective tax rate was ~~22.5~~21.0 percent in ~~2021~~2022 and ~~22.7~~20.9 percent in ~~2020.~~2021.

~~Kimberly-Clark’s~~Our share of net income of equity companies in the ~~second~~first quarter was ~~$28~~$23 in ~~2021~~2022 and ~~$35~~$39 in ~~2020.~~2021. Equity results were negatively impacted by input cost inflation.

Diluted net income per share for the ~~second~~first quarter of 2022 was ~~$1.19~~$1.55 and $1.72 in ~~2021 and $1.99 in 2020. Second~~2021. First quarter adjusted earnings per share were ~~$1.47~~$1.35 in ~~2021,~~2022, a decrease of 3325 percent compared to ~~$2.20~~$1.80 in ~~2020.~~

Year-to-date net sales of $9.5 billion decreased 2 percent compared to the year ago period. Organic sales decreased 5 percent, as volumes declined 7 percent and changes in net selling prices and product mix each increased sales by 1 percent. Changes in foreign currency exchange rates increased sales by approximately 2 percent and the net impact of the Softex Indonesia acquisition and business exits in conjunction with the 2018 Global Restructuring Program increased sales by 2 percent. Year-to-date operating profit was $1,383 in 2021 and $1,829 in 2020. Results in both periods include charges related to the 2018 Global Restructuring Program. Year-to-date adjusted operating profit was $1,480 in 2021 and $2,009 in 2020. Results were impacted by lower sales volumes, higher input costs and elevated other manufacturing costs. Results benefited from higher net selling prices, $180 of FORCE savings and $70 of cost savings from the 2018 Global Restructuring Program. Through six months, diluted net income per share was $2.92 in 2021 and $3.92 in 2020. Year-to-date adjusted earnings per share were $3.27 in 2021 and $4.34 in 2020.2021.

Results by Business Segments

Personal Care


		Three Months Ended June 30				Six Months Ended June 30					Three Months Ended June 30				Six Months Ended June 30					Three Months Ended March 31					Three Months Ended March 31
		2021		2020		2021		2020			2021		2020		2021		2020			2022		2021				2022		2021
Net Sales	Net Sales	$	2,517	$	2,229	$	4,979	$	4,651	Operating Profit	$	454	$	519	$	935	$	1,046	Net Sales	$	2,729	$	2,462		Operating Profit	$	475	$	481

Net Sales	Net Sales	Percent Change				Percent Change				Operating Profit	Percent Change				Percent Change				Net Sales			Percent Change		Operating Profit		Percent Change
Volume	Volume			4				—		Volume			1				(3)		Volume			3			Volume			1
Net Price	Net Price			—				—		Net Price			(1)				(1)		Net Price			8			Net Price			40
Mix/Other	Mix/Other			2				2		Input Costs			(28)				(19)		Mix/Other			3			Input Costs			(44)
Acquisition/Exited Businesses(e)				4				4		Cost Savings(c)			10				10
Currency	Currency			3				1		Currency Translation			2				1		Currency			(2)			Cost Savings(c)			5
Total(a)	Total(a)			13				7		Other(d)			3				1		Total(a)			11			Currency Translation			(3)
																									Other(d)			—
Organic(b)	Organic(b)			6				2		Total			(13)				(11)		Organic(b)			13			Total			(1)

(a) Total may not equal the sum of volume, net price, mix/other ~~acquisition/exited businesses~~ and currency due to rounding.

(b) Combined impact of changes in volume, net price and mix/other.

(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.

~~(e)~~First quarter net sales in North America increased 16 percent. Changes in net selling prices and product mix increased sales by 8 percent and 3 percent, respectively. Volumes rose 5 percent, in part due to the weather-related supply chain disruptions in the year-ago period. Organic sales were up double-digits in baby & child care, adult care and feminine care.

Net sales in D&E markets increased 8 percent. Changes in net selling prices and product mix increased sales by 9 percent and 3 percent, respectively, while volumes declined 1 percent. Changes in foreign currency exchange rates decreased sales by 3 percent. Organic sales growth was strong across all regions and categories.

Net sales in developed markets outside North Americaincreased 5 percent. Volumes increased 8 percent and changes in net selling prices increased sales by 4 percent, while changes in foreign currency exchange rates decreased sales by 7 percent.

Operating profit of $475 decreased 1 percent.The comparison was impacted by input cost inflation, higher marketing, research and general expense as well as unfavorable foreign currency effects. Results benefited from organic sales growth and cost savings.

Consumer Tissue


	Three Months Ended March 31					Three Months Ended March 31
	2022		2021					2022		2021
Net Sales	$	1,568	$	1,510			Operating Profit	$	171	$	269

Net Sales			Percent Change		Operating Profit			Percent Change
Volume			2				Volume			(1)
Net Price			5				Net Price			26
Mix/Other			—				Input Costs			(66)
Exited businesses(e)			(1)				Cost Savings(c)			7
Currency			(2)				Currency Translation			—
Total(a)			4				Other(d)			(2)
Organic(b)			7				Total			(36)

(a) Total may not equal the sum of volume, net price, mix/other, exited businesses and currency due to rounding.

(b) Combined impact of changes in volume, net price and mix/other.

(d) Includes impact of ~~Softex Indonesia~~changes in marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.

(e) Impact of exited businesses in conjunction with the 2018 Global Restructuring Program.

~~Second~~First quarter net sales in North America increased 29 percent. Volumes grew 6 percent and changes in net selling prices increased sales by 4 percent, while unfavorable changes in product mix decreased sales by 1 percent. The volume growth reflects comparison to the start of COVID-related consumer and retailer inventory destocking in the year-ago period.

Net sales in D&E markets increased 3 percent. Changes in net selling prices increased sales by approximately 7 percent and changes in product mix increased sales by 1 percent, while volumes were down 2 ~~percent, driven by baby and child care, and changes~~percent. Changes in foreign currency exchange rates ~~increased~~decreased sales by 12 percent.

Net sales in developed markets outside North America decreased 5 percent. Exited businesses related to the 2018 Global Restructuring ~~Program~~program reduced sales by ~~1 percent.~~

~~Net sales in D&E markets increased 24 percent. The Softex Indonesia acquisition increased sales by 14~~4 percent, ~~while~~and changes in foreign currency exchange rates ~~increased~~decreased sales by 26 percent. Volumes ~~rose 6~~were down 1 percent, ~~and the combined impact of~~while changes in net selling prices ~~and product mix~~ increased sales by ~~2 percent. Organic sales increased in Argentina, Brazil, China, India and throughout the Middle East, Africa, Eastern Europe region but declined in ASEAN and most of the rest of Latin America.~~

~~Net sales in developed markets outside North America increased 26 percent. Changes in foreign currency exchange rates increased sales by 14 percent and volumes rose 12~~approximately 6 percent.

Operating profit of ~~$454~~$171 decreased 1336 percent. ~~Results were~~The comparison was impacted by input cost inflation and higher ~~other manufacturing cost increases while the comparison~~marketing, research and general expense. Results benefited from organic sales growth, lower other manufacturing costs and cost savings.

K-C Professional

~~Consumer Tissue~~


		Three Months Ended June 30				Six Months Ended June 30					Three Months Ended June 30				Six Months Ended June 30					Three Months Ended March 31					Three Months Ended March 31
		2021		2020		2021		2020			2021		2020		2021		2020			2022		2021				2022		2021
Net Sales	Net Sales	$	1,424	$	1,645	$	2,934	$	3,368	Operating Profit	$	196	$	428	$	465	$	793	Net Sales	$	780	$	752		Operating Profit	$	90	$	126

Net Sales	Net Sales	Percent Change				Percent Change				Operating Profit	Percent Change				Percent Change				Net Sales			Percent Change		Operating Profit		Percent Change
Volume	Volume			(15)				(15)		Volume			(30)				(27)		Volume			—			Volume			(13)
Net Price	Net Price			—				—		Net Price			(1)				—		Net Price			4			Net Price			25
Mix/Other	Mix/Other			(1)				(1)		Input Costs			(30)				(22)		Mix/Other			1			Input Costs			(63)
Currency	Currency			3				2		Cost Savings(c)			18				14		Currency			(2)			Cost Savings(c)			6
Total(a)	Total(a)			(13)				(13)		Currency Translation			1				2		Total(a)			4			Currency Translation			(1)
																									Other(d)			17
Organic(b)	Organic(b)			(17)				(15)		Other(d)			(12)				(8)		Organic(b)			6			Total			(29)
										Total			(54)				(41)

(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.

(b) Combined impact of changes in volume, net price and mix/other.

~~(d) Includes impact of changes in marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.~~

Second quarter net sales in North America decreased 26 percent. Volumes fell 27 percent and changes in product mix decreased sales by 2 percent, while changes in net selling prices increased sales by 2 percent.

Net sales in D&E markets increased 9 percent including a 3 percent favorable impact from changes in foreign currency exchange rates. Volumes rose 3 percent and changes in product mix increased sales by 1 percent, while changes in net selling prices decreased sales by 2 percent. The Softex Indonesia acquisition increased sales by 4 percent.

Net sales in developed markets outside North America increased 1 percent, including a 10 percent benefit from changes in foreign currency exchange rates. Changes in net selling prices decreased sales by 6 percent, compared to very low promotion levels in the year-ago period, and volumes were down 1 percent. Exited businesses related to the 2018 Global Restructuring Program reduced sales by 2 percent.

Operating profit of $196 decreased 54 percent. The comparison was impacted by lower organic sales, higher input costs and other manufacturing cost increases, including inefficiencies from lower production volumes. Results benefited from cost savings, lower advertising spending and favorable currency effects.

~~K-C Professional~~
Three Months Ended June 30 Six Months Ended June 30

Three Months Ended June 30 Six Months Ended June 30
2021 2020 2021 2020 2021 2020 2021 2020
Net Sales $ 765 $ 724 $ 1,517 $ 1,572 Operating Profit $ 110 $ 155 $ 236 $ 336
Net Sales Percent Change Percent Change Operating Profit Percent Change Percent Change
Volume (4) (13) Volume (18) (31)
Net Price 5 6 Net Price 25 29
Mix/Other 1 1 Input Costs (45) (34)
Currency 3 2
Cost Savings(c)
11 11
Total(a)
6 (3) Currency Translation 3 2
Organic(b)
2 (6)
Other(d)
(5) (7)
Total (29) (30)

~~(a) Total may not equal the sum of volume, net price, mix/other and currency due to rounding.~~

~~(b) Combined impact of changes in volume, net price and mix/other.~~

~~(c) Combined benefits of the FORCE program and 2018 Global Restructuring Program.~~program.

(d) Includes impact of changes in product mix, marketing, research and general expenses, foreign currency transaction effects and other manufacturing costs.

~~Second~~

First quarter net sales in North America ~~decreased 3~~increased 5 percent. ~~Volumes were down 11 percent, while changes~~Changes in net selling prices ~~increased sales by approximately 6 percent~~ and ~~changes in~~ product mix increased sales by ~~2 percent. Sales~~4 percent and 1 percent, respectively. Washroom products sales were ~~down mid-teens in washroom products and wipers~~up strong double-digits, while sales ~~increased double-digits in~~of wipers and safety ~~and other~~ products ~~mostly due to higher net selling prices and favorable product mix.~~slowed versus a strong year-ago.

Net sales in D&E markets increased ~~31 percent including a~~4 percent. Changes in net selling prices and product mix increased sales by 3 percent ~~benefit from changes~~and 2 percent, respectively, and volumes grew by 2 percent. Changes in foreign currency exchange ~~rates. Volumes rose 24 percent, compared to a soft year-ago period, while changes in net selling prices increased~~rates decreased sales by 53 percent.

Net sales in developed markets outside North America ~~increased 13 percent including an 11 percent benefit from changes in foreign currency exchange rates.~~were even with the year-ago period. Changes in net selling prices and product mix increased sales by 5 percent and 3 percent, respectively, while volumes decreased ~~approximately 2~~1 percent. Changes in foreign currency exchange rates reduced sales by 7 percent.

Operating profit of ~~$110~~$90 decreased 29 percent. The comparison was impacted by ~~lower volumes~~input cost inflation and higher ~~input costs.~~marketing, research and general expense. Results benefited from ~~increased net selling prices~~organic sales growth, lower other manufacturing costs and cost savings.

~~2018 Global Restructuring Program~~

Second quarter 2021 pre-tax savings from the 2018 Global Restructuring Program were $30, bringing cumulative savings to $495. See Item 1, Note 2 to the unaudited interim consolidated financial statements for additional information.

~~To implement this program, we expect to incur incremental capital spending of approximately $600 to $700 by the end of 2021.~~

Liquidity and Capital Resources

Cash Provided by Operations

Cash provided by operations was ~~$886~~$204 for the first ~~six~~three months of ~~2021~~2022 compared to ~~$2,283~~$321 in the prior year. The ~~decrease~~decline was driven by lower ~~earnings, working capital increase in accounts receivable and inventory, payments for accrued expenses and timing of tax payments.~~operating profit.

Investing

During the ~~six~~three months ended ~~June 30, 2021,~~March 31, 2022, our capital spending was ~~$499~~$253 compared to ~~$636~~$298 in the prior year. We anticipate that full year capital spending will be ~~$1.1~~ $1.0 billion to ~~$1.2 billion, which is down from our prior estimate as~~$1.1 billion. Acquisition of business, net of cash acquired of $34 in the first quarter ~~2021~~ of ~~$1.2 billion to $1.3 billion.~~2022 reflected the acquisition of a controlling interest of Thinx.

Financing

Our short-term debt, which consists of U.S. commercial paper with original maturities up to 90 days and/or other similar short-term debt issued by non-U.S. subsidiaries, was ~~$1.2~~$1.0 billion as of ~~June 30, 2021~~March 31, 2022 (included in Debt payable within one year on the consolidated balance sheet). The average month-end balance of short-term debt for the ~~second~~first quarter of ~~2021~~2022 was ~~$1.3~~$0.9 billion. These short-term borrowings provide supplemental funding ~~for supporting~~to support our operations. The level of short-term debt

generally fluctuates depending upon the amount of operating cash flows and the timing of customer receipts and payments for items such as dividends and income taxes.

At ~~June 30, 2021~~March 31, 2022 and December 31, ~~2020,~~2021, total debt was $9.1 billion and ~~$8.4~~ $8.6 billion, respectively.

We maintain a $2.0 billion revolving credit facility which expires in June 2026 and a $750 revolving credit facility which expires in June 2022. These facilities, currently unused, support our commercial paper program, and would provide liquidity in the event our access to the commercial paper markets is unavailable for any reason.

~~In July 2017, the~~The United ~~Kingdom's~~Kingdom’s Financial Conduct Authority, which regulates the London Interbank Offered Rate ~~(LIBOR)~~(“LIBOR”), ~~announced that it intends to~~is in the process of phasing out LIBOR with completion of the phase out ~~LIBOR~~expected by ~~the end of 2021.~~ June 30, 2023. We ~~are currently evaluating~~have evaluated the potential effect of the ~~eventual replacement~~elimination of ~~the~~ LIBOR ~~but we~~and do not expect the effect to be material. Accounting guidance has been issued to ease the transition to alternative reference rates from a financial reporting perspective.

We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. During the first ~~six~~three months of ~~2021,~~2022, we repurchased ~~2.5 million~~214 thousand shares of our common stock at a cost of ~~$336~~$27 through a ~~broker~~broker in the open market. We ~~expect our~~are targeting full-year 2022 share repurchases ~~will be $400~~of approximately $100, subject to ~~$450, which is down from our prior estimate as of first quarter 2021 of $650 to $750.~~

~~K-C Argentina began accounting for their operations as highly infl~~ationary effective July 1, 2018, as required by GAAP. Under highly inflationary accounting, K-C Argentina’s functional currency became the U.S. dollar, and its income statement and balance sheet have been measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on peso-denominated monetary assets and liabilities has been reflected in earnings in Other (income) and expense, net and was not material. As of June 30, 2021, K-C Argentina had a small net peso monetary position. Net sales of K-C Argentina were approximately 1 percent of our consolidated net sales for the three and six months ended June 30, 2021.market conditions.

We believe that our ability to generate cash from operations and our capacity to issue short-term and long-term debt are adequate to fund working capital, ~~payments for our 2018 Global Restructuring Program,~~ capital spending, pension contributions, dividends and other needs for the foreseeable future. Further, we do not expect restrictions or taxes on repatriation of cash held outside of the U.S. to have a material effect on our overall business, liquidity, financial condition or results of operations for the foreseeable future.

Information Concerning Forward-Looking Statements

Certain matters contained in this report concerning the business outlook, including raw material, energy and other input costs, the anticipated cost savings from our FORCE program, ~~costs and savings from the 2018 Global Restructuring Program,~~ cash flow and uses of cash, growth initiatives, innovations, marketing and other spending, net sales, anticipated currency rates and exchange risks, including the impact in Argentina, effective tax rate, contingencies and anticipated transactions of Kimberly-Clark, including dividends, share repurchases and pension contributions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995 and are based upon management's expectations and beliefs concerning future events impacting Kimberly-Clark. There can be no assurance that these future events will occur as anticipated or that our results will be as estimated. Forward-looking statements speak only as of the date they were made, and we undertake no obligation to publicly update them.

The assumptions used as a basis for the forward-looking statements include many estimates that, among other things, depend on the achievement of future cost savings and projected volume increases. In addition, many factors outside our ~~control,~~control, including the war in Ukraine (including the related responses of consumers, customers, and suppliers and sanctions issued by the U.S., the European Union, Russia or other countries), pandemics (including the ongoing COVID-19 outbreak and the related responses of governments, consumers, customers, suppliers and employees), epidemics, fluctuations in foreign currency exchange rates, the prices and availability of our raw materials, supply chain disruptions, ~~due to COVID-19,~~ changes in customer preferences, ~~(including consumer tissue destocking following a COVID-19 related stock up in 2020),~~ severe weather conditions, or government trade or similar regulatory actions, potential competitive pressures on selling prices for our products, energy costs, general economic and political conditions globally and in the markets in which we do business, as well as our ability to maintain key customer relationships, ~~and to realize the expected benefits and synergies of the Softex Indonesia acquisition,~~ could affect the realization of these estimates.

~~For a description of certain~~The factors ~~that~~described under Item 1A, "Risk Factors" in this Form 10-K, or in our other SEC filings, among others, could cause our future results to differ from those expressed in ~~these~~any forward-looking statements ~~see Item 1A of~~made by us or on our ~~Annual Report on Form 10-K for the year ended December 31, 2020 entitled "Risk Factors."~~behalf. Other factors not presently known to us or that we presently consider immaterial could also affect our business operations and financial results.

Item 4. Controls and Procedures

As of ~~June 30, 2021,~~March 31, 2022, an evaluation was performed under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure

controls and procedures. Based on that evaluation, management, including the Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of ~~June 30, 2021.~~March 31, 2022. There were no changes in our internal control over financial reporting during the quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2319

PART II – OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

We repurchase shares of Kimberly-Clark common stock from time to time pursuant to publicly announced share repurchase programs. All our share repurchases during the ~~second~~first quarter of ~~2021~~2022 were made through a broker in the open market.

The following table contains information for shares repurchased during the ~~second~~first quarter of ~~2021.~~2022. None of the shares in this table were repurchased directly from any of our officers or directors.

Period (2021)
Total Number
of Shares
Purchased(a)
Average
Price Paid
Per Share Total Number of
Shares Purchased
as Part of Publicly
Announced Plans
or Programs
Maximum Number
of Shares That May
Yet Be Purchased
Under the Plans or
Programs(b)
April 1 to April 30 405,800 $ 136.24 37,030,376 42,969,624
May 1 to May 31 374,800 133.70 37,405,176 42,594,824
June 1 to June 30 426,800 130.38 37,831,976 42,168,024
Total 1,207,400


Period (2022)	Total Number of Shares Purchased(a)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs(b)
January 1 to January 31	10,500	$	137.56	38,320,083	41,679,917
February 1 to February 28	87,300	132.31		38,407,383	41,592,617
March 1 to March 31	117,000	123.38		38,524,383	41,475,617
Total	214,800

(a)Share repurchases were made pursuant to a share repurchase program authorized by our Board of Directors on November 13, 2014. This program allows for the repurchase of 40 million shares in an amount not to exceed $5 billion (the "2014 Program").

(b)Includes shares under the 2014 Program, as well as available shares under a share repurchase program authorized by our Board of Directors on January 22, 2021 that allows for the repurchase of 40 million shares in an amount not to exceed $5 billion.

2420

Item 6. Exhibits

(a)Exhibits

Exhibit No. (3)a. Restated Certificate of Incorporation, as amended April 29, 2021, incorporated by reference to Exhibit No. (3)a of the Corporation's Current Report on Form 8-K filed on April 29, 2021.

~~Exhibit No. (3)b. By-Laws, as amended April 29, 2021, incorporated by reference to Exhibit No. (3)b of the Corporation's Current Report on Form 8-K filed on April 29, 2021.~~

~~Exhibit No. (4). Copies of instruments defining the rights of holders of long-term debt will be furnished to the Securities and Exchange Commission on request.~~

~~Exhibit No. (10)k~~ ~~2021 Outside Directors' Compensation Plan effective April 29, 2021, incorporated by reference to Exhibit No. (10)k of the~~ ~~Corporation's Current Report on Form 8-K filed on April 29, 2021.~~

~~Exhibit No. (10)~~n . ~~Form of Award Agreements~~ ~~under~~20 21 ~~Equity Participation Plan for Nonqualified Stock Options, filed herewith.~~

~~Exhibit No. (10)~~o ~~2021~~ ~~Equity Participation~~ ~~Plan effective April 29, 2021, incorporated by reference to Exhibit No.(10)~~o ~~of the Corporation's Current Report on Form 8-K filed on April 29, 2021.~~

Exhibit No. (10)q. Form of Award Agreements under ~~2021 Equity Participation Plan for Performance~~ ~~Restricted Stock Units, filed herewith.~~

~~Exhibit No. (10)~~r ~~. Form of Award Agreements under~~ 20 212 1 Equity Participation Plan for ~~Time-Vested~~Performance Restricted Stock Units, filed herewith .

Exhibit No. (10)r. Form of Award Agreements under 2021 Equity Participation Plan for Time-Vested Restricted Stock Units, filed herewith.

Exhibit No. (31)a. Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), filed herewith.

Exhibit No. (31)b. Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), filed herewith.

Exhibit No. (32)a. Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code, furnished herewith.

Exhibit No. (32)b. Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) of the Exchange Act and Section 1350 of Chapter 63 of Title 18 of the United States Code, furnished herewith.

Exhibit No. (101).INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

Exhibit No. (101).SCH XBRL Taxonomy Extension Schema Document

Exhibit No. (101).CAL XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit No. (101).DEF XBRL Taxonomy Extension Definition Linkbase Document

Exhibit No. (101).LAB XBRL Taxonomy Extension Label Linkbase Document

Exhibit No. (101).PRE XBRL Taxonomy Extension Presentation Linkbase Document

Exhibit No. 104 The cover page from this Current Report on Form 10-Q ~~formated~~formatted as Inline XBRL

2521

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



						KIMBERLY-CLARK CORPORATION
						(Registrant)







By:						/s/ Andrew S. Drexler
						Andrew S. Drexler
						Vice President and Controller
						(principal accounting officer)

~~July 23, 2021~~April 22, 2022

2622


	Six Months Ended June 30, 2021
(Millions of dollars, shares in thousands, except per share amounts)	Common Stock Issued			Additional Paid-in Capital		Treasury Stock			Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Non-controlling Interests		Total Stockholders' Equity
	Shares	Amount				Shares	Amount
Balance at December 31, 2020	378,597	$	473	$	657	39,873	$	(4,899)	$	7,567	$	(3,172)	$	243	$	869
Net income in stockholders' equity, excludes redeemable interests' share	—	—		—		—	—		988		—		15		1,003
Other comprehensive income, net of tax, excludes redeemable interests' share	—	—		—		—	—		—		(43)		(7)		(50)
Stock-based awards exercised or vested	—	—		(77)		(952)	104		—		—		—		27
Shares repurchased	—	—		—		2,740	(364)		—		—		—		(364)
Recognition of stock-based compensation	—	—		41		—	—		—		—		—		41
Dividends declared ($2.28 per share)	—	—		—		—	—		(770)		—		(17)		(787)
Other	—	—		6		—	—		13		—		—		19
Balance at June 30, 2021	378,597	$	473	$	627	41,661	$	(5,159)	$	7,798	$	(3,215)	$	234	$	758


	Three Months Ended June 30, 2020
(Millions of dollars, shares in thousands, except per share amounts)	Common Stock Issued			Additional Paid-in Capital		Treasury Stock			Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Non-controlling Interests		Total Stockholders' Equity
	Shares	Amount				Shares	Amount
Balance at March 31, 2020	378,597	$	473	$	559	37,761	$	(4,562)	$	6,978	$	(3,615)	$	213	$	46
Net income in stockholders' equity, excludes redeemable interests' share	—	—		—		—	—		681		—		10		691
Other comprehensive income, net of tax, excludes redeemable interests' share	—	—		—		—	—		—		102		4		106
Stock-based awards exercised or vested	—	—		(38)		(557)	66		—		—		—		28
Shares repurchased	—	—		—		370	(49)		—		—		—		(49)
Recognition of stock-based compensation	—	—		38		—	—		—		—		—		38
Dividends declared ($1.07 per share)	—	—		—		—	—		(365)		—		—		(365)
Other	—	—		(5)		—	—		5		—		—		—
Balance at June 30, 2020	378,597	$	473	$	554	37,574	$	(4,545)	$	7,299	$	(3,513)	$	227	$	495


Period (2021)	Total Number of Shares Purchased(a)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs(b)
April 1 to April 30	405,800	$	136.24	37,030,376	42,969,624
May 1 to May 31	374,800	133.70		37,405,176	42,594,824
June 1 to June 30	426,800	130.38		37,831,976	42,168,024
Total	1,207,400